Generic neffy Availability
Last updated on Apr 10, 2025.
neffy is a brand name of epinephrine, approved by the FDA in the following formulation(s):
NEFFY (epinephrine - spray;nasal)
-
Manufacturer: ARS PHARMS OPERATION
Approval date: August 9, 2024
Strength(s): 2MG/SPRAY [RLD] -
Manufacturer: ARS PHARMS OPERATION
Approval date: March 5, 2025
Strength(s): 1MG/SPRAY [RLD]
Is there a generic version of neffy available?
No. There is currently no therapeutically equivalent version of neffy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of neffy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions for drug administration
Patent 10,576,156
Issued: March 3, 2020
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLCThe present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Patent expiration dates:
- February 6, 2038✓
- February 6, 2038
-
Intranasal epinephrine formulations and methods for the treatment of disease
Patent 10,682,414
Issued: June 16, 2020
Inventor(s): Lowenthal Richard & Maggio Edward T. & Bell Robert G. & Shah Pratik
Assignee(s): AEGIS THERAPEUTICS, LLCDrug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Patent expiration dates:
- February 6, 2039✓
- February 6, 2039
-
Compositions for drug administration
Patent 11,173,209
Issued: November 16, 2021
Inventor(s): Maggio Edward T.
Assignee(s): AEGIS THERAPEUTICS, LLCThe present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Patent expiration dates:
- February 6, 2038✓
- February 6, 2038
-
Intranasal epinephrine formulations and methods for the treatment of disease
Patent 11,191,838
Issued: December 7, 2021
Inventor(s): Lowenthal Richard & Maggio Edward T. & Bell Robert G. & Shah Pratik
Assignee(s): AEGIS THERAPEUTICS, LLCDrug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Patent expiration dates:
- February 6, 2039✓✓
- February 6, 2039
-
Intranasal epinephrine formulations and methods for the treatment of disease
Patent 11,717,571
Issued: August 8, 2023
Inventor(s): Lowenthal; Richard et al.
Assignee(s): AEGIS THERAPEUTICS, LLC (San Diego, CA)Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Patent expiration dates:
- February 6, 2039✓
- February 6, 2039
-
Intranasal epinephrine formulations and methods for the treatment of disease
Patent 11,744,895
Issued: September 5, 2023
Inventor(s): Lowenthal; Richard et al.
Assignee(s): AEGIS THERAPEUTICS, LLC (San Diego, CA)Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Patent expiration dates:
- February 6, 2039✓
- February 6, 2039
-
Intranasal epinephrine formulations and methods for the treatment of disease
Patent 11,918,655
Issued: March 5, 2024
Inventor(s): Lowenthal; Richard et al.
Assignee(s): AEGIS THERAPEUTICS, LLC (San Diego, CA)Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Patent expiration dates:
- February 6, 2039✓
- February 6, 2039✓✓
- February 6, 2039
More about neffy (epinephrine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenergic bronchodilators
- Breastfeeding
Patient resources
Other brands
EpiPen, Adrenalin, Primatene Mist, Auvi-Q, ... +5 more
Professional resources
Other brands
EpiPen, Adrenalin, Primatene Mist, Auvi-Q, ... +4 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.